Indivior (INDV) director buys more shares in open-market trade

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. director Ryan Barbara reported an open-market purchase of common stock. On March 9, 2026, Ryan Barbara bought 31 shares of Indivior common stock at $32.56 per share. After this trade, the director directly owns 5,716 shares of Indivior common stock.

Insider Trade Summary

Net Buyer: 31 shares

Net Buy 1 txn

Insider Ryan Barbara

Role Director

Bought 31 shs ($1K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	31	$32.56	$1K

Holdings After Transaction: Common Stock — 5,716 shares (Direct)

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/11/2026 - 08:12 AM Learn about SEC filing dates

FAQ

What insider transaction did Indivior (INDV) report for Ryan Barbara?

Indivior reported that director Ryan Barbara bought 31 shares of common stock in an open-market transaction. The purchase was recorded at a price of $32.56 per share on March 9, 2026.

How many Indivior (INDV) shares did Ryan Barbara buy and at what price?

Ryan Barbara bought 31 shares of Indivior common stock at $32.56 per share. This was an open-market purchase and reflects a relatively small increase in the director’s personal holdings.

What are Ryan Barbara’s total Indivior (INDV) holdings after the Form 4 trade?

Following the March 9, 2026 transaction, Ryan Barbara directly owns 5,716 shares of Indivior common stock. This total includes the 31 shares purchased in the reported open-market transaction.

Was the Indivior (INDV) insider transaction a buy or sell?

The reported Indivior insider transaction was a buy. Director Ryan Barbara executed an open-market purchase of 31 shares of common stock at $32.56 per share, increasing directly held shares to 5,716.

Did the Indivior (INDV) Form 4 include any derivative securities?

No, the reported Indivior Form 4 only shows a non-derivative transaction in common stock. There were no option exercises, warrants, or other derivative security transactions listed in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ryan Barbara

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VA 23235

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		P		31	A	$32.56	5,716	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/Alice Givens, Power of Attorney	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.